Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study.

@article{Yu2014SafetyAE,
  title={Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study.},
  author={Shiying Yu and Wei Shen and Lu Yu and Yanyan Hou and John Han and Henry M. Richards},
  journal={The journal of pain : official journal of the American Pain Society},
  year={2014},
  volume={15 8},
  pages={
          835-44
        }
}
UNLABELLED Noninferiority of the efficacy of once-daily hydromorphone hydrochloride extended-release (hydromorphone ER) compared with twice-daily oxycodone hydrochloride controlled-release (oxycodone CR) was investigated in this randomized, double-blind study in Chinese patients with moderate to severe cancer pain requiring strong oral opioid analgesics. Randomization (1:1) to hydromorphone ER (8-32 mg) or oxycodone CR (10-40 mg) was followed by dose titration (up to 8 days) and dose… CONTINUE READING